teaser
Lemtrada (alemtuzumab) has been submitted to the European Medicines Agency and the US Food and Drug Administration for the treatment of patients with relapsing–remitting multiple sclerosis.
Submission of the drug, already licensed as leukaemia treatment Campath, follows release of long-term data for the only approved pill for treatment of relapsing forms of MS – Gilenya – yesterday.
Significant data supporting alemtuzumab include a Phase III study published in 2011 which demonstrated superior efficacy to standard treatment with interferon beta-1a.
